COMMUNIQUÉS West-GlobeNewswire

EDAP TMS SA : EDAP Announces CIGNA as First Major U.S. Private Health Insurer to Cover HIFU for Prostate Procedure
21/03/2018
Insurer Takes its Cue from Updated NCCN Guidelines, Which Recognizes HIFU as Salvage Treatment for Prostate Cancer Lyon, France, Austin, TX -- March 21, 2018 - EDAP TMS SA (Nasdaq: EDAP) today announced that CIGNA [...]
Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc.
21/03/2018
RANCHO CUCAMONGA, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH ) announced that on March 20, 2018, the United States Court for the District of Massachusetts (the “District [...]
PotNetwork Holding Inc. Leadership Appears on The Mick Bazsuly Show, Projects 60-70% Gains in Revenues for 2018
21/03/2018
FORT LAUDERDALE, Fla., March 21, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- PotNetwork Holding Inc. (OTC Pink:POTN) On Tuesday the 20th of March in 2018, PotNetwork Holding Inc. CEO Dr. Richard Goulding and Senior [...]
RavenQuest Obtains OTCQB Listing Under Symbol “RVVQF”
21/03/2018
VANCOUVER, British Columbia, March 21, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB) (OTCQB:RVVQF) (Frankfurt: 1IT ) is pleased to announce that OTC Markets Group Inc. has [...]
Amarin Announces First Middle East Approval for Vascepa®
21/03/2018
BEDMINSTER, N.J. and DUBLIN, Ireland, March 21, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
Helsinn Group announces agreement to acquire worldwide rights to Valchlor/Ledaga, an approved and marketed alkylating agent for topical treatment of mycosis fungoides type cutaneous T-cell lymphoma
21/03/2018
Helsinn Group announces agreement to acquire worldwide rights to Valchlor ® /Ledaga ® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides- type cutaneous T- cell lymphoma, a rare [...]
Notice Convening the Annual General Meeting
21/03/2018
March 21, 2018 Announcement no. 6 Notice Convening the Annual General Meeting The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S: April 13, 2018, at 3.00 pm (CET), At the Company’s address [...]
Veritas Pharma Completes the 100% Takeover of Cannevert Therapeutics
21/03/2018
VANCOUVER, British Columbia, March 21, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ) ( “ Veritas ” or the “Company”) is pleased to announce the Company has completed the 100% [...]
DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
21/03/2018
Montrouge, France, March 21, 2018 DBV Technologies Announces Pricing of $150.0 million ( € 122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the " [...]
DBV Technologies annonce le prix de son offre globale d'actions ordinaires, pouvant prendre la forme d'American Depositary Shares, pour un montant total de 150 millions de dollars américains
21/03/2018
Montrouge, France, 21 Mars 2018, 8h00 CET DBV Technologies annonce le prix de son offre globale d'actions ordinaires, pouvant prendre la forme d'American Depositary Shares, pour un montant total de 150 millions de [...]
Financière de Tubize SA: Convening of the ordinary and extraordinary general meetings of shareholders of the 25th of April 2018
21/03/2018
Financière de Tubize SA/NV Allée de la Recherche 60 1070 Brussels BE 0403.216.429 www.financiere-tubize.be CONVENING OF THE ORDINARY AND EXTRAORDINARY GENERAL MEETINGS OF SHAREHOLDERS OF 25 APRIL 2018 The shareholders [...]
Financière de Tubize SA: Convocation de l'assemblée générale ordinaire et de l'assemblée générale extraordinaire des actionnaires du 25 avril 2018
21/03/2018
Financière de Tubize SA Allée de la Recherche 60 1070 Bruxelles BE 0403.216.429 www.financiere-tubize.be CONVOCATION DE L'ASSEMBLEE GENERALE ORDINAIRE DES ACTIONNAIRES ET DE L'ASSEMBLEE GENERALE EXTRAORDINAIRE DU 25 [...]
MHRA Grants UK Patients Early Access to Akcea Therapeutics’ Volanesorsen for Familial Chylomicronaemia Syndrome (FCS)
21/03/2018
LONDON, March 21, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics United Kingdom (UK) Ltd today announced that volanesorsen has been granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
21/03/2018
REGULATED INFORMATION GHENT, Belgium, 21 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
Bone Therapeutics SA : Information on the total number of voting rights and shares
21/03/2018
Regulated information Information on the total number of voting rights and shares Gosselies, Belgium, 21 March 2018, 7am CET - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company [...]
Bone Therapeutics SA : Information relative au nombre total de droits de vote et d'actions
21/03/2018
Information réglementée Information relative au nombre total de droits de vote et d'actions Gosselies, Belgique, le 21 mars 2018, 7h00 CET - BONE THERAPEUTICS (code Euronext Bruxelles et Paris: BOTHE), société de [...]
Sorrento Therapeutics CEO Dr Ji to Present at Needham 17th Annual Healthcare Conference on 03/27/18
21/03/2018
SAN DIEGO, March 20, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ) ("Sorrento"), announced today that Dr Ji will present at the Needham 17 th Annual Healthcare Conference in NYC on March 27 th [...]
XORTX Announces Issuance of Stock Options
21/03/2018
CALGARY, Alberta, March 20, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney [...]
scPharmaceuticals Inc. Reports Fourth Quarter 2017 Financial Results
21/03/2018
Announced $147.7 Million of equity capital raising in 2017; Completed an Initial Public Offering; Advances towards FUROSCIX™ PDUFA date BURLINGTON, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. ( [...]

Pages